XAIR News and Press, Beyond Air Inc. From 12/13/22

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, announced today the publication of pre-clini...

GARDEN CITY, N.Y., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hyp...

Data showing UNO in combination with anti-PD-1 treatment leads to significantly higher tumor regression rates UNO in combination with anti-PD-1 treatment results in a higher percentage of tumor free mice and prolonged survival in CT26 tumor bearing mice GARDEN CITY, N.Y. a...

Beyond Air, Inc. (XAIR) Q2 2023 Results Earnings Conference Call November 8, 2022, 04:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas L...

Beyond Air press release ( NASDAQ: XAIR ): FQ2 GAAP EPS of -$0.40 misses by $0.03 . As of September 30, 2022, the Company reported cash and cash equivalents, marketable securities, and restricted cash of $72.5 million. For further details see: Beyond Air GAAP...

Commercial launch underway for LungFit ® PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022 Presented favorable safety, tolerability, and efficacy results from the pilot study of at-home Lun...

-- Duration of oxygen support was significantly shorter for subjects treated with inhaled NO LungFit PRO safely delivered 150 ppm NO in the hospital-- GARDEN CITY, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutic...

GARDEN CITY, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hyp...

Shares of micro-cap Beyond Air, a medical device company developing inhaled nitric oxide systems for lung diseases, snapped a seven-day losing streak on Monday, earlier ending 3.6% higher at $6.03. The company after hours announced data from its at-home pilot study of its Lung...

-- Data show favorable safety, tolerability, and efficacy results -- -- All patients titrated to 250 ppm NO with no patients needing to reduce concentration -- -- All patients demonstrated ability to self-administer NO at home using the easy-to-operate and compact novel ...